scPharmaceuticals Inc. (SCPH)
SCPH moved a median of +0.09% 30 minutes after news, and +0.36% by the close. How SCPH actually reacts to news — the realized, point-in-time move the market made, measured across 180 labeled events over the last three years with zero look-ahead.
SCPH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 149 |
| 30-min | +0.09% | 50% | 149 |
| 60-min | +0.25% | 63% | 149 |
| to close | +0.36% | 56% | 149 |
| Middle 50% of SCPH reactions | -1.07% to +1.74% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 180 |
Half of all scPharmaceuticals Inc. news events land between -1.07% and +1.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SCPH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SCPH's baseline. Nothing else.
Recent SCPH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G scPharmaceuticals Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K scPharmaceuticals Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM scPharmaceuticals Inc. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS scPharmaceuticals Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care | Press release | GlobeNewswire | — | — | |
| Form 8-K scPharmaceuticals Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +0.00% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +0.36% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +0.36% | |
| MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases | Press release | GlobeNewswire | -0.27% | +0.36% | |
| SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind | Press release | GlobeNewswire | +0.09% | +0.09% | |
| SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders | Press release | Business Wire | -0.27% | +0.36% | |
| scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 | Press release | GlobeNewswire | -0.84% | +4.21% | |
| Form 10-Q scPharmaceuticals Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.10% | -2.94% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -2.10% | -2.94% | |
| scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.10% | -2.94% | |
| scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 | Press release | GlobeNewswire | +0.03% | +3.19% | |
| Form 8-K scPharmaceuticals Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.47% | |
| Form 10-Q scPharmaceuticals Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +22.50% | +30.91% | |
| Form 8-K scPharmaceuticals Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +22.50% | +30.91% | |
| scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +22.50% | +30.91% | |
| scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 | Press release | GlobeNewswire | +0.00% | +4.15% | |
| scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +2.73% | +1.56% | |
| Form DEF 14A scPharmaceuticals Inc. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | -1.95% | +1.95% | |
| Form DEFA14A scPharmaceuticals Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.95% | +1.95% | |
| Form 10-K scPharmaceuticals Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.54% | +1.01% | |
| Form 8-K scPharmaceuticals Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +5.54% | +1.01% | |
| Form S-8 scPharmaceuticals Inc. | SEC filing · Form S-8 | SEC EDGAR | +5.54% | +1.01% | |
| scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.54% | +1.01% | |
| scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 | Press release | GlobeNewswire | -2.28% | -0.66% | |
| scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease | Press release | GlobeNewswire | -1.72% | -9.29% | |
| scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +0.60% | -2.70% | |
| scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +2.10% | -1.80% | |
| Form 8-K scPharmaceuticals Inc. For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -4.24% | -3.96% | |
| scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results | Press release | GlobeNewswire | -4.24% | -3.96% | |
| Form 10-Q/A scPharmaceuticals Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.28% | +0.28% | |
| Form 8-K scPharmaceuticals Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -2.95% | +0.29% | |
| Form 10-Q scPharmaceuticals Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.79% | -4.00% | |
| Form 8-K scPharmaceuticals Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | -4.00% | |
| scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.79% | -4.00% | |
| scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 | Press release | GlobeNewswire | +1.15% | -0.69% | |
| scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 | Press release | GlobeNewswire | +0.71% | +1.19% | |
| scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Press release | GlobeNewswire | -0.20% | +1.17% | |
| Form 10-Q scPharmaceuticals Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.39% | +5.64% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +5.39% | +5.64% | |
| scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.39% | +5.64% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | +11.04% | |
| Form 8-K scPharmaceuticals Inc. For: Aug 09 | SEC filing · Form 8-K | SEC EDGAR | +6.02% | +6.75% | |
| scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure | Press release | GlobeNewswire | +6.02% | +6.75% | |
| scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors | Press release | GlobeNewswire | +6.02% | +6.75% | |
| scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector | Press release | GlobeNewswire | +6.02% | +6.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SCPH section they belong to.
Where else SCPH is measured.
SCPH earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | 180 | 0.00% | 48% |
| BIO BLAST PHARMA LTD ORDINARY (ORPN) | 180 | 0.00% | 35% |
| vTv Therapeutics Inc. - Class A (VTVT) | 180 | 0.00% | 39% |
| SOL GLOBAL INVTS CORP (SOLCF) | 179 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is scPharmaceuticals Inc.'s median reaction calculated?
Every labeled SCPH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 180 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of SCPH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SCPH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.